Abstract: The present invention relates to the design, synthesis, and biological study of multi-targeted Ubenimex pro-drug derivative. More particularly, provided in the present invention is a compound as shown by general structural formula (I) (wherein the definition of R is shown in the description). The derivative is a multi-targeted compound obtained by binding an aminopeptidase (APN/CD13) inhibitor, Ubenimex, with some anti-tumor drugs already on the market through an ester bond or amide bond, and is suitable for use as an anti-tumor drug for the treating various malignant tumors, and is especially suitable for treating various solid tumors.
Type:
Grant
Filed:
June 6, 2014
Date of Patent:
January 9, 2018
Assignee:
Jinan Platinum Pharmatech Co. Ltd.
Inventors:
Wenfang Xu, Yuqi Jiang, Yingjie Zhang, Mingming Zou, Jinning Hou, Jin Li, Xuejian Wang, Xiaoyang Li